XTL Biopharmaceuticals Sponsored ADR (XTLB) AI Stock Analysis

• Market Cap: $6.61M
• Dividend Yield: N/A
• Average Volume (3M): 98.27K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.45
• Revenue Growth: N/A
• EPS Growth: 65.45%
• Country: US
• Employees: 10
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.14
• Shares Outstanding: 9,462,434
• 10 Day Avg. Volume: 49,384
• 30 Day Avg. Volume: 98,272
• PEG Ratio: 0.00
• Price to Book (P/B): 0.63
• Price to Sales (P/S): 7.57
• P/FCF Ratio: -2.04
• Enterprise Value/Market Cap: 0.48
• Enterprise Value/Revenue: 7.06
• Enterprise Value/Gross Profit: 26.75
• Enterprise Value/Ebitda: -4.02
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 39 Underperform
• Price Target: ―

XTL Biopharmaceuticals Ltd. shows considerable financial difficulties with persistent losses and weak cash flow. The technical analysis aligns with a bearish outlook, while valuation metrics highlight an unattractive investment at present. Although the stock has seen a recent price surge, the absence of earnings call details makes future performance uncertain.

Positive Factors

Pipeline Development

The company's focus on developing therapeutic candidates for unmet medical needs in autoimmune diseases and oncology indicates a strong potential for future growth and market relevance, as successful drug development can lead to significant revenue streams from licensing and sales.

Strategic Collaborations

Strategic collaborations with pharmaceutical companies for co-development or out-licensing of drug candidates can provide XTL Biopharmaceuticals with essential funding, expertise, and market access, enhancing its ability to bring products to market and generate revenue.

Low Debt Profile

Maintaining a low debt profile provides XTL Biopharmaceuticals with greater financial flexibility and reduces the risk of financial distress, allowing the company to focus resources on R&D and strategic initiatives without the burden of high-interest obligations.

Negative Factors

Negative Cash Flow

Persistent negative cash flow highlights liquidity challenges, limiting the company's ability to invest in growth opportunities and sustain operations without external funding, which could hinder long-term strategic objectives and financial stability.

High Liabilities

A high level of liabilities compared to assets indicates financial instability, which could constrain XTL Biopharmaceuticals' ability to secure additional financing or invest in R&D, potentially impacting its ability to advance its drug pipeline and achieve profitability.

Persistent Net Losses

Ongoing net losses and negative EBIT margins reflect operational inefficiencies and a lack of revenue generation, posing a challenge to achieving profitability and requiring the company to rely on external funding to sustain operations and invest in future growth.

XTL Biopharmaceuticals Sponsored ADR Business Overview & Revenue Model

Company Description

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

How the Company Makes Money

XTL Biopharmaceuticals generates revenue primarily through the development and commercialization of proprietary drug candidates targeting autoimmune diseases and cancer. The company may earn money from licensing agreements, milestone payments, and royalties related to its drug development programs. Key revenue streams include partnerships with other pharmaceutical companies for the co-development or out-licensing of its drug candidates, as well as potential sales of approved products. Additionally, the company may receive research grants and funding from governmental or non-governmental organizations to support its R&D activities.

XTL Biopharmaceuticals Sponsored ADR Financial Statement Overview

Summary

XTL Biopharmaceuticals Ltd. faces ongoing financial headwinds, with significant net losses and negative EBIT margins. Despite a slight improvement in stockholders' equity, the company struggles with high liabilities and negative cash flows, reflecting operational inefficiencies typical in the biotech sector.

Income Statement

The income statement reflects significant challenges with persistent net losses and negative EBIT margins due to the absence of revenue. The company's profitability trajectory is concerning, with inconsistent net income figures over the years. The lack of revenue growth further exacerbates the financial instability, indicating potential operational inefficiencies in the biotechnology sector.

Balance Sheet

The balance sheet shows a slight improvement in stockholders' equity, moving from negative to positive in the most recent year. However, the overall financial stability remains weak due to high liabilities relative to assets. The company benefits from a low debt profile, but the equity ratio indicates a fragile financial structure that may pose risks in sustaining operations.

Cash Flow

The cash flow statement reveals consistent negative free cash flow and operating cash flow, highlighting liquidity challenges. The cash flow to net income ratios indicate inefficiencies in converting net losses to positive cash flow. Although there is some improvement in cash flow from investing activities, the overall cash flow management remains a concern.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	451.00K	0.00	0.00	0.00	0.00
Gross Profit	3.00K	0.00	-1.00K	-1.00K	-1.00K
EBITDA	-930.00K	-764.00K	-879.00K	-1.03M	-947.00K
Net Income	-1.03M	-1.78K	-1.35M	435.00K	-782.00K
Balance Sheet
Total Assets	8.55M	2.43M	4.19M	6.62M	6.50M
Cash, Cash Equivalents and Short-Term Investments	1.14M	2.01M	3.72M	6.13M	6.04M
Total Debt	138.00K	0.00	0.00	0.00	0.00
Total Liabilities	3.12M	206.00K	187.00K	1.28M	254.00K
Stockholders Equity	5.43M	2.22M	4.00M	5.33M	3.61M
Cash Flow
Free Cash Flow	-1.67M	-707.00K	-901.00K	-1.05M	-851.00K
Operating Cash Flow	-1.62M	-707.00K	-901.00K	-1.05M	-850.00K
Investing Cash Flow	-844.00K	41.00K	36.00K	8.00K	32.00K
Financing Cash Flow	1.45M	0.00	0.00	385.00K	0.00

XTL Biopharmaceuticals Sponsored ADR Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.69
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XTLB, the sentiment is Negative. The current price of 0.69 is below the 20-day moving average (MA) of 0.74, below the 50-day MA of 0.85, and below the 200-day MA of 1.19, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 42.08 is Neutral, neither overbought nor oversold. The STOCH value of 55.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XTLB.

XTL Biopharmaceuticals Sponsored ADR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LPCN	51 Neutral	$41.81M	-7.41	-32.92%	―	-44.31%	-34.17%
EDSA	50 Neutral	$12.58M	-1.12	-99.57%	―	―	30.29%
COCP	45 Neutral	$15.16M	-1.18	-94.94%	―	―	49.10%
ALLR	42 Neutral	$19.11M	-0.74	-122.61%	―	―	99.82%
XTLB	39 Underperform	$6.61M	-6.18	―	―	―	65.45%
CARM	39 Underperform	$1.89M	0.24	―	―	159.68%	―

XTL Biopharmaceuticals Sponsored ADR Corporate Events

XTL Biopharmaceuticals Takes Major Impairment on The Social Proxy in First-Half 2025 Results

On December 30, 2025, XTL Biopharmaceuticals reported financial results for the six months ended June 30, 2025, highlighting a near-full write-down of its subsidiary The Social Proxy following a prolonged dispute with the unit’s former shareholders and the resignation of its key executives earlier in December 2025. The impairment of The Social Proxy’s intangible assets and goodwill drove substantial non-cash charges, including increases in cost of services and sales and marketing expenses and a $3.2 million goodwill impairment, which contributed to a sharp widening of the net loss to $5.5 million from $0.2 million a year earlier. While revenue reached $0.5 million for the period due to consolidating The Social Proxy for the first time, XTL’s liquidity weakened as cash and marketable securities fell to about $0.25 million, and the company noted that no updated data had been received from the subsidiary after June 30, 2025. The company also recorded significant finance income from the cancellation and revaluation of warrant liabilities related to The Social Proxy transaction, and, despite a post–first half 2025 legal claim and ongoing disputes with the former shareholders, it concluded that no litigation provision was warranted at this stage, underscoring continued uncertainty over the strategic and financial value of the acquisition.

XTL Biopharmaceuticals Faces Nasdaq Bid-Price Deficiency, Given Until June 2026 to Regain Compliance

On December 24, 2025, XTL Biopharmaceuticals announced it had received a Nasdaq notification, dated December 22, 2025, stating that the company’s American Depositary Shares had failed to meet the exchange’s minimum bid price requirement of $1 per share for the prior 30 consecutive business days, triggering a formal compliance period. While the notice does not immediately affect trading of XTL’s ADSs on Nasdaq, the company now has 180 calendar days, until June 22, 2026, to lift its share price back above the $1 threshold for at least ten consecutive business days or risk potential delisting, with the possibility of an additional 180-day extension if it meets other listing criteria and pursues measures such as a reverse stock split. XTL said it is evaluating options to regain compliance, and the development underscores ongoing market pressure on the stock and raises uncertainty for shareholders over the company’s continued access to U.S. capital markets.

XTL Biopharmaceuticals Faces Leadership Changes at Social Proxy Subsidiary

On December 11, 2025, XTL Biopharmaceuticals Ltd. announced the immediate resignation of Tal Klinger, CEO, and Roee Klinger, CTO, from Social Proxy Ltd., its wholly owned subsidiary. The company is currently assessing the management strategy for Social Proxy Ltd. and will provide updates as necessary, indicating a potential shift in leadership dynamics that could impact its operational focus.

XTL Biopharmaceuticals Announces CFO Transition Amid Strategic Appointments

On December 5, 2025, XTL Biopharmaceuticals announced the resignation of its Chief Financial Officer, Mr. Itay Weinstein, effective December 11, 2025. His departure was not due to any disagreements with the company. To fill the vacancy, the Board of Directors appointed Mr. Niv Segal as the new CFO on November 30, 2025. Mr. Segal brings over 12 years of financial management experience, particularly in the high-tech sector, with notable achievements in leading major acquisitions.

XTL Biopharmaceuticals Announces Board Changes Following Resignation

On October 21, 2025, Doron Turjeman resigned from the Board of Directors of XTL Biopharmaceuticals Ltd. due to personal reasons, with no disagreements with the company. Subsequently, Noam Band, the CEO, was appointed to the board, potentially strengthening the company’s leadership and strategic direction.